NCT04198766Phase 1, phase 2Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Study sponsor: Inhibrx Biosciences, Inc · INBX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2033-07Estimated
Enrollment · participants340Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.